Pluristem Therapeutics Inc. (NASDAQ:PSTI) Short Interest Update

Pluristem Therapeutics Inc. (NASDAQ:PSTI) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 358,400 shares, a decrease of 31.2% from the August 15th total of 520,600 shares. Based on an average daily volume of 238,100 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.3% of the company’s stock are short sold.

Several institutional investors and hedge funds have recently modified their holdings of PSTI. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Pluristem Therapeutics in the 2nd quarter valued at approximately $53,000. Susquehanna International Group Ltd. acquired a new stake in shares of Pluristem Therapeutics in the 2nd quarter valued at approximately $55,000. UBS Group AG boosted its holdings in shares of Pluristem Therapeutics by 22.2% in the 1st quarter. UBS Group AG now owns 20,069 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 3,649 shares during the last quarter. Walleye Trading LLC acquired a new stake in shares of Pluristem Therapeutics in the 1st quarter valued at approximately $125,000. Finally, Algert Global LLC acquired a new stake in shares of Pluristem Therapeutics in the 1st quarter valued at approximately $130,000. 14.23% of the stock is owned by institutional investors.

NASDAQ PSTI traded down $0.14 during trading hours on Monday, reaching $2.86. 212,237 shares of the company’s stock were exchanged, compared to its average volume of 480,367. Pluristem Therapeutics has a one year low of $2.81 and a one year high of $11.85. The company’s 50-day moving average is $3.20 and its two-hundred day moving average is $3.93.

Pluristem Therapeutics (NASDAQ:PSTI) last issued its quarterly earnings results on Sunday, September 12th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.06). On average, analysts predict that Pluristem Therapeutics will post -1.52 EPS for the current year.

Separately, Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 13th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Pluristem Therapeutics has an average rating of “Buy” and an average price target of $9.35.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics, Inc is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies.

Featured Article: What moving averages are used to define a golden cross?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.